Results: 11
Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2064, doi. 10.1111/1759-7714.14529
- By:
- Publication type:
- Article
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2057, doi. 10.1111/1759-7714.14528
- By:
- Publication type:
- Article
Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2050, doi. 10.1111/1759-7714.14523
- By:
- Publication type:
- Article
Modified Glasgow prognostic score predicts the prognosis of patients with advanced esophageal squamous cell carcinoma: A propensity score‐matched analysis.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2041, doi. 10.1111/1759-7714.14486
- By:
- Publication type:
- Article
Predictive value of post‐treatment C‐reactive protein‐to‐albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2031, doi. 10.1111/1759-7714.14484
- By:
- Publication type:
- Article
Angiosarcoma of breast and chest wall complicated with tuberculous empyema: A case report.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2078, doi. 10.1111/1759-7714.14482
- By:
- Publication type:
- Article
Outcome and prognosis of secondary lung cancer surgery with interstitial lung disease.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2024, doi. 10.1111/1759-7714.14481
- By:
- Publication type:
- Article
A rare case of docetaxel‐induced myositis in a patient with a lung adenocarcinoma.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2075, doi. 10.1111/1759-7714.14480
- By:
- Publication type:
- Article
TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2014, doi. 10.1111/1759-7714.14478
- By:
- Publication type:
- Article
Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2005, doi. 10.1111/1759-7714.14477
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 14, p. 2003, doi. 10.1111/1759-7714.14028
- Publication type:
- Article